ImmunoGen

• NCT05320380

  Collaborator, Phase 1/2, Withdrawn, 0 people, Apr 11, 2022

• NCT03836157

  Collaborator, Phase 2, Withdrawn, 0 people, Feb 11, 2019

• Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors

  Collaborator, Phase 1, Completed, 173 people, Apr 5, 2017

• A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer

  Phase 3, Completed, 366 people, Dec 16, 2015

• Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer

  Phase 1/2, Completed, 264 people, Nov 17, 2015

• A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer

  Phase 1/2, Terminated, 181 people, Nov 9, 2010

Sources: clinicaltrials.gov

• The Impact of Climate Vulnerability on Cancer Incidence Among U.S. Women

  Consulting or advice, Fees or honoraria, Grants or research support, Jan 28, 2026

• Curcuma-Based Nutritional Supplements and Risk of Age-Related Macular Degeneration

  Consulting or advice, Fees or honoraria, Dec 1, 2024

• Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study

  Grants or research support, Feb 4, 2022

Sources: pubmed.ncbi.nlm.nih.gov